Kueh, Martin T. W. http://orcid.org/0000-0002-7473-343X
Chew, Nicholas W. S.
Al-Ozairi, Ebaa http://orcid.org/0000-0001-5006-4369
le Roux, Carel W. http://orcid.org/0000-0001-5521-5445
Article History
Received: 18 July 2023
Revised: 14 November 2023
Accepted: 23 November 2023
First Online: 14 December 2023
Competing interests
: CWleR: ClR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI. Dynamics, Eli Lilly, Johnson & Johnson, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He was the chief medical officer and director of the Medical Device Division of Keyron in 2011. Both of these are unremunerated positions. ClR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron’s products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron’s studies and they are not listed on the stock market. ClR was gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.